胃癌铂类化疗预后与XRCC1多态性关系
Single nucleotide polymorphisms in XRCC1 and outcome in gastric cancer patients receiving oxaliplatin based chemotherapy
-
摘要: 目的 探讨外周血X线交错互补修复基因1(XRCC1)单核苷酸多态性与接受铂类药物化疗胃癌患者生存时间关系。方法 经病理确诊胃癌患者62例,治疗前提取其外周血DNA,采用TaqMan探针Real-time PCR方法对XRCC1第399位密码子进行多态性分析,并比较其基因型与接受铂类化疗患者生存时间关系。结果 62例胃癌患者平均总生存时间为461 d,携带XRCC1 Arg/Arg或Arg/Gln基因型胃癌患者的平均总生存时间为490 d,而携带Gln/Gln基因型患者的平均总生存时间仅为295 d,差异有统计学意义(P=0.022)。结论 XRCC1基因多态性与接受铂类化疗的胃癌患者的总生存时间明显相关。Abstract: Objective To investigate whether the single nucleotide polymorphism(SNP)in DNA repair gene XRCC1 (X-ray repair cros-sco mplementing 1)were associated with the survival of 5-FU/oxaliplatin combination chemotherapy in gastric cancer.Methods Overau survival time of 62 gastric cancer patients receiving platinum-based chemotherapy were investigated.XRCC1 genot ypes were assessed using 5c nuclease allelic discrimination assay(TaqMan)using real-time PCR.Results The median sur vival time of all 62 gastric patients was 461 days.The median surv ival time of patients with Arg/Arg or Arg/Gln genoty pes was 490 days compared with 295 days of others(P=0.022).Conclusion XRCC1 399 SNP was predictive marker of survival for gastric cancer patients receiving platinum-based chemotherapy.
下载: